[{"id":"e0be9b49-8cbc-4688-a452-7aaedd1a1b20","acronym":"","url":"https://clinicaltrials.gov/study/NCT05228015","created_at":"2022-02-12T17:47:53.327Z","updated_at":"2024-07-02T16:35:09.961Z","phase":"Phase 1","brief_title":"Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT05228015","lead_sponsor":"Ikena Oncology","biomarkers":" YAP1 • TFE3 • CAMTA1 • TAFAZZIN","pipe":" | ","alterations":" TFE3 fusion","tags":["YAP1 • TFE3 • CAMTA1 • TAFAZZIN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TFE3 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • IK-930"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 01/07/2022","start_date":" 01/07/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-04-12"},{"id":"5e4173a0-f1b6-45fa-9023-3e3fc9e7ede2","acronym":"YAPPETIZER","url":"https://clinicaltrials.gov/study/NCT03358017","created_at":"2021-01-18T16:34:31.703Z","updated_at":"2024-07-02T16:35:32.529Z","phase":"Phase 2","brief_title":"Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer","source_id_and_acronym":"NCT03358017 - YAPPETIZER","lead_sponsor":"Mario Negri Institute for Pharmacological Research","biomarkers":" HER-2 • TP53 • PGR • BRCA • TAFAZZIN","pipe":" | ","alterations":" PGR negative","tags":["HER-2 • TP53 • PGR • BRCA • TAFAZZIN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zoledronic acid • atorvastatin"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 03/05/2018","start_date":" 03/05/2018","primary_txt":" Primary completion: 06/17/2021","primary_completion_date":" 06/17/2021","study_txt":" Completion: 07/25/2023","study_completion_date":" 07/25/2023","last_update_posted":"2023-10-19"},{"id":"0832f425-1674-469e-b2f7-05cb2959cee1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05103644","created_at":"2021-11-02T17:57:09.080Z","updated_at":"2024-07-02T16:36:01.226Z","phase":"Phase 2/3","brief_title":"Study of the Therapeutic Effect of Atorvastatin on the Clinical Outcomes in HER2 Negative Breast Cancer Patients\"","source_id_and_acronym":"NCT05103644","lead_sponsor":"Beni-Suef University","biomarkers":" HER-2 • WWTR1 • TAFAZZIN","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • WWTR1 • TAFAZZIN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atorvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/30/2021","start_date":" 10/30/2021","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2022-11-02"}]